title: Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.
abstract: In the rabbit model of Streptococcus pneumoniae meningitis, treatment with rifabutin, quinupristin-dalfopristin, moxifloxacin and trovafloxacin led to smaller increases of the CSF concentrations of the pro-inflammatory cell wall components lipoteichoic and teichoic acids (LTA and TA) than did treatment with ceftriaxone. Low doses of moxifloxacin were associated with higher LTA and TA concentrations in CSF than were high doses.
authors.affiliation: Department of Neurology, University of Göttingen, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Stuertz
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: F
authors.initials: F
authors.lastname: Trostdorf
authors.forename: H
authors.initials: H
authors.lastname: Eiffert
authors.forename: M
authors.initials: M
authors.lastname: Mäder
authors.forename: R
authors.initials: R
authors.lastname: Nau
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000008:administration & dosage; D001372:Aza Compounds; D002443:Ceftriaxone / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage; D004195:Disease Models, Animal; D024841:Fluoroquinolones; D007124:Immunoenzyme Techniques; D008070:Lipopolysaccharides / Q000134:cerebrospinal fluid*; D008586:Meningitis, Pneumococcal / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D000077266:Moxifloxacin; D009287:Naphthyridines / Q000008:administration & dosage; D011135:Polysaccharides, Bacterial / Q000134:cerebrospinal fluid; D011804:Quinolines; D011817:Rabbits; D012016:Reference Values; D017828:Rifabutin / Q000008:administration & dosage*; D013682:Teichoic Acids / Q000134:cerebrospinal fluid*; D014769:Virginiamycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D002511:Cephalosporins; D024841:Fluoroquinolones; D008070:Lipopolysaccharides; D009287:Naphthyridines; D011135:Polysaccharides, Bacterial; D011804:Quinolines; D013682:Teichoic Acids; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D017828:Rifabutin; C009900:lipoteichoic acid; D002443:Ceftriaxone; C080163:trovafloxacin; D000077266:Moxifloxacin